Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.

@article{Maurer2013OmalizumabFT,
  title={Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.},
  author={Marcus Maurer and Karin E. Ros{\'e}n and Hsin-ju Hsieh and Sarbjit S. Saini and Clive E Grattan and Ana M Gim{\'e}nez-Arnau and Sunil Agarwal and Ramona Doyle and Janice Canvin and Allen P. Kaplan and Thomas B. Casale},
  journal={The New England journal of medicine},
  year={2013},
  volume={368 10},
  pages={
          924-35
        }
}
BACKGROUND Many patients with chronic idiopathic urticaria (also called chronic spontaneous urticaria) do not have a response to therapy with H-antihistamines, even at high doses. In phase 2 trials, omalizumab, an anti-IgE monoclonal antibody [corrected] that targets IgE and affects mast-cell and basophil function, has shown efficacy in such patients. METHODS In this phase 3, multicenter, randomized, double-blind study, we evaluated the efficacy and safety of omalizumab in patients with… 

Figures and Tables from this paper

Ligelizumab for Chronic Spontaneous Urticaria.

A higher percentage of patients had complete control of symptoms of chronic spontaneous urticaria with ligelIZumab therapy of 72 mg or 240 mg than with omalizumab or placebo.

Efficacy of Omalizumab in Treatment-Resistant Chronic Spontaneous Urticaria

Omalizumab is a good treatment option, thanks to its efficacy and safety, in chronic spontaneous urticaria patients who do not respond to H1-antihistamines.

Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria who Remain Symptomatic on H1 Antihistamines: A Randomized, Placebo-Controlled Study.

Omalizumab 300 mg administered subcutaneously every 4 weeks reduced weekly ISS and other symptom scores versus placebo in CIU/CSU patients who remained symptomatic despite treatment with approved doses of H 1 antihistamines.

Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic on H1 Antihistamines: A Randomized, Placebo-Controlled Study

Omalizumab 300 mg administered subcutaneously every 4 weeks reduced weekly ISS and other symptom scores versus placebo in CIU/CSU patients who remained symptomatic despite treatment with approved doses of H1 antihistamines.

Omalizumab for chronic urticaria.

  • T. Casale
  • Medicine
    The journal of allergy and clinical immunology. In practice
  • 2014

Therapeutic Challenges in Chronic Spontaneous Urticaria

  • M. Ünsel
  • Medicine
    Cyprus Journal of Medical Sciences
  • 2022
Evidence that combined drug use may be much more effective than monotherapy in CSU is provided, and cyclosporine and methotrexate may be beneficial in the management of CSU which is unresponsive to conventional treatments.

Omalizumab in the treatment of antihistamine-resistant chronic urticaria in adults.

The Use of Omalizumab in Chronic Urticaria: Available Data and Future Aspects of Anti-IgE Treatment

  • Y. Ye
  • Medicine, Biology
  • 2021
A new anti-IgE treatment, ligelIZumab is actively evaluated in the efficacy compared with both placebo and omalizumab, and further understandings on the pathogenesis of CU can lead to the development of new mechanism-based therapeutics for CU patients.

Chronic idiopathic urticaria: treatment with omalizumab.

Omalizumab has emerged as a very promising treatment option for patients with CSU and it is necessary to establish standardized protocols related to dosing as well as monitoring possible adverse effects of long-term treatment.
...

References

SHOWING 1-10 OF 48 REFERENCES

Treatment of chronic autoimmune urticaria with omalizumab.

Etoricoxib challenge in patients with chronic urticaria with NSAID intolerance

  • R. Asero
  • Medicine
    Clinical and experimental dermatology
  • 2007
The study suggests that etoricoxib, with its favourable COX‐1/COX‐2 ratio, is well tolerated by patients with chronic urticaria exacerbated by NSAID intolerance.

Chronic unremitting urticaria: is the use of antihistamines above the licensed dose effective? A preliminary study of cetirizine at licensed and above‐licensed doses

  • R. Asero
  • Medicine
    Clinical and experimental dermatology
  • 2007
The proportion of patients with severe CU that may gain a better control of their disease with high, off‐label doses of antihistamines is probably small, and that most patients will eventually have to undergo more aggressive treatments.

Development of a daily diary for patients with chronic idiopathic urticaria.

The impact of chronic idiopathic urticaria on quality of life in korean patients.

It is suggested that CIU has a negative impact on quality of life (QOL) in Korean patients and it is important to recognize the effects CIU can have on QOL and consider them in evaluating the response to treatment.

New concepts in chronic urticaria.

Evaluating the minimally important difference of the urticaria activity score and other measures of disease activity in patients with chronic idiopathic urticaria.